Avastin® Added Safely to Paraplatin® and Camptosar® for Small Cell Lung Cancer
According to the results of a study presented at the 12th World Conference on Lung Cancer, the targeted therapy Avastin® (bevacizumab) can be safely added to chemotherapy with Paraplatin® (carboplatin) and Camptosar® (irinotecan) in patients with extensive-stage small cell lung cancer.
Lung cancer is the leading cause of cancer-related deaths in the United States and Europe. The two main types of lung cancer are small cell lung cancer (SCLC) and non–small cell lung cancer. Small cell lung cancer is less common than non-small cell lung cancer.
This entry was posted on Monday, November 5th, 2007 at 5:42 pm and is filed under Research, Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.